¿Qué dice la ciencia sobre el CBD?

En este post ponemos a vuestra disposición algunos de los estudios relacionados con el CBD publicados hasta la fecha.


    ·    Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) [Internet]. 2013 Apr [cited 2021 Mar 2];226(4):781–92. Available from:

    ·    Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry [Internet]. 2012 [cited 2021 Mar 1];2(3). Available from:

    ·    Bergamaschi MM, Helena Costa Queiroz R, Hortes M, Chagas N, Chaves Gomes De Oliveira D, De Martinis BS, et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naı¨veNaı¨ve Social Phobia Patients. Neuropsychopharmacology [Internet]. 2011 [cited 2021 Feb 25];36:1219–26. Available from:

   ·   Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J [Internet]. 2016 Sep 1 [cited 2021 Mar 2];20(4):108–11. Available from:

    ·    Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series.

  ·    P. Soares V, C. Campos A. Evidences for the Anti-panic Actions of Cannabidiol. Curr Neuropharmacol [Internet]. 2016 Jun 8 [cited 2021 Mar 1];15(2):291–9. Available from:

·    Schier AR de M, Ribeiro NP de O, e Silva AC de O, Hallak JEC, Crippa JAS, Nardi AE, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr [Internet]. 2012 Jun [cited 2021 Mar 1];34:S104–17. Available from:

·    Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders [Internet]. Vol. 174, British Journal of Pharmacology. John Wiley and Sons Inc.; 2017 [cited 2021 Mar 1]. p. 3242–56. Available from:

·    Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: A critical overview. Vol. 27, Epidemiology and Psychiatric Sciences. Cambridge University Press; 2018. p. 327–35.

·    Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Vol. 12, Neurotherapeutics. Springer New York LLC; 2015. p. 825–36.

·    Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci [Internet]. 2016 Jul 8 [cited 2021 Mar 3];39:1–17. Available from: /pmc/articles/PMC5818147/


·    Vilela LR, Gomides LF, David BA, Antunes MM, Diniz AB, De Araújo Moreira F, et al. Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. Mediators Inflamm [Internet]. 2015 [cited 2021 Mar 3];2015. Available from:

·    Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, et al. Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology [Internet]. 2018 Sep 1 [cited 2021 Mar 3];43(10):2036–45. Available from:

·    Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M, et al. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage [Internet]. Vol. 12, Neurotherapeutics. Springer New York LLC; 2015 [cited 2021 Mar 3]. p. 807–15. Available from:

·    Hahn B. The Potential of Cannabidiol Treatment for Cannabis Users with Recent-Onset Psychosis. Schizophr Bull [Internet]. 2018 Jan 1 [cited 2021 Mar 3];44(1):46–53. Available from:

·    Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav [Internet]. 2018 Nov 1 [cited 2021 Mar 3];88:162–71. Available from:

·    Chye Y, Christensen E, Solowij N, Yücel M. The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry [Internet]. 2019 [cited 2021 Mar 3];10(FEB). Available from:

·    De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, et al. Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain [Internet]. Vol. 10, Frontiers in Pharmacology. Frontiers Media S.A.; 2019 [cited 2021 Mar 3]. Available from:

·    Batalla A, Janssen H, Gangadin SS, Bossong MG. The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. J Clin Med [Internet]. 2019 Jul 19 [cited 2021 Mar 3];8(7):1058. Available from:

·    Calpe-López C, Pilar García-Pardo M, Aguilar MA. Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms [Internet]. Vol. 24, Molecules. MDPI AG; 2019 [cited 2021 Mar 3]. Available from:


·    Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. antioxidants Antioxidative and Anti-Inflammatory Properties of Cannabidiol. [cited 2021 Feb 21]; Available from:

·     CBD May Reduce Period Pain and Menstrual Cramps [Internet]. [cited 2021 Mar 2]. Available from:

·    Rajesh M, Mukhopadhyay P, Btkai S, Patel V, Saito K, Matsumoto S, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol [Internet]. 2010 Dec 14 [cited 2021 Mar 1];56(25):2115–25. Available from:

·    Kicman A, Toczek M. The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease [Internet]. Vol. 21, International Journal of Molecular Sciences. MDPI AG ; 2020 [cited 2021 Mar 1]. p. 1–45. Available from:

·    Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults [Internet]. Vol. 2018, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2018 [cited 2021 Mar 1]. Available from:

·    Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Vol. 23, Bioorganic and Medicinal Chemistry. Elsevier Ltd; 2015. p. 1377–85.

·    King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, et al. Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol [Internet]. 2017 [cited 2021 Mar 1];174(17):2832–41. Available from:

·    Gusho CA, Court T. Cannabidiol: A Brief Review of Its Therapeutic and Pharmacologic Efficacy in the Management of Joint Disease. Cureus [Internet]. 2020 Mar 23 [cited 2021 Mar 3];12(3). Available from:

·    Armour M, Sinclair J, Chalmers KJ, Smith CA. Self-management strategies amongst Australian women with endometriosis: A national online survey. Vol. 19, BMC Complementary and Alternative Medicine. BioMed Central Ltd.; 2019.


·     Pesántez Ríos G, Armijos-Acurio L, Jimbo-Sotomayor R, Pascual-Pascual SI, Pesántez-Cuesta G. Cannabidiol: Its use in refractory epilepsies. Rev Neurol [Internet]. 2017 Aug 16 [cited 2021 Mar 1];65(4):157–60. Available from:

·     Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. molecules Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. [cited 2021 Mar 1]; Available from:

·     Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy [Internet]. Vol. 12, Neurotherapeutics. Springer New York LLC; 2015 [cited 2021 Mar 3]. p. 747–68. Available from:

·    Pickrell WO, Robertson NP. Cannabidiol as a treatment for epilepsy. J Neurol. 2017 Dec 1;264(12):2506–8.

·     Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia [Internet]. 2016 Oct 1 [cited 2021 Mar 1];57(10):1617–24. Available from:

·     Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, et al. Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia [Internet]. 2019 Feb 1 [cited 2021 Mar 1];60(2):303–14. Available from:

·    Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia [Internet]. 2018 Aug 1 [cited 2021 Mar 1];59(8):1540–8. Available from:

·    Ryan M. Cannabidiol in epilepsy: The indications and beyond. Ment Heal Clin [Internet]. 2020 Nov 1 [cited 2021 Mar 3];10(6):317–25. Available from:

·    Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Front Neurol [Internet]. 2019 Dec 10 [cited 2021 Mar 3];10. Available from:

·    Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia [Internet]. 2014 [cited 2021 Mar 1];55(6):791–802. Available from:

· Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, et al. Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord [Internet]. 2020 Feb 1 [cited 2021 Mar 3];22(1):1–14. Available from:


·    Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol [Internet]. 2017 Aug 1 [cited 2021 Mar 3];27(8):795–808. Available from:

· Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, Hommel B. Modulation of cognitive and emotional processing by cannabidiol: The role of the anterior cingulate cortex. Front Hum Neurosci [Internet]. 2013 Apr 4 [cited 2021 Mar 3];7(APR 2013). Available from:

·   Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, Van Hell H, et al. Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. Cannabis Cannabinoid Res [Internet]. 2018 Mar 1 [cited 2021 Mar 3];3(1):21–34. Available from:


·    Wang J, Lu H, Wang J. Cannabinoid receptors in osteoporosis and osteoporotic pain: a narrative update of review. J Pharm Pharmacol [Internet]. 2019 Sep 3 [cited 2021 Mar 3];71(10):1469–74. Available from:

·   TAU researcher: cannabis can help heal bone fractures | Tel Aviv University | Tel Aviv University [Internet]. [cited 2021 Mar 3]. Available from:

·   Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: From marijuana to reversal of bone loss [Internet]. Vol. 41, Annals of Medicine. Ann Med; 2009 [cited 2021 Mar 3]. p. 560–7. Available from:

·    Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, et al. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. J Bone Miner Res [Internet]. 2015 Oct 1 [cited 2021 Mar 3];30(10):1905–13. Available from:

·    I. Idris A. Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Curr Neuropharmacol [Internet]. 2010 Aug 19 [cited 2021 Mar 3];8(3):243–53. Available from:

·    Silveira JW, Issy AC, Castania VA, Salmon CEG, Nogueira-Barbosa MH, Guimarães FS, et al. Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration. PLoS One [Internet]. 2014 Dec 17 [cited 2021 Mar 3];9(12). Available from:


·    Chagas MHN, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther [Internet]. 2014 Oct 1 [cited 2021 Mar 2];39(5):564–6. Available from:

·    Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett [Internet]. 2006 Aug 7 [cited 2021 Mar 2];580(18):4337–45. Available from:

·    Chagas MHN, Crippa JAS, Zuardi AW, Hallak JEC, MacHado-De-Sousa JP, Hirotsu C, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol [Internet]. 2013 Mar [cited 2021 Mar 2];27(3):312–6. Available from:

·    Murillo-Rodríguez E, Budde H, Veras AB, Rocha NB, Telles-Correia D, Monteiro D, et al. The Endocannabinoid System May Modulate Sleep Disorders in Aging. Curr Neuropharmacol [Internet]. 2019 Aug 1 [cited 2021 Mar 3];18(2):97–108. Available from:

·    Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23.


·    Sangiovanni E, Fumagalli M, Pacchetti B, Piazza S, Magnavacca A, Khalilpour S, et al. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phyther Res [Internet]. 2019 Aug 1 [cited 2021 Mar 1];33(8):2083–93. Available from:

·    Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic potential of cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig Dermatol [Internet]. 2020 [cited 2021 Mar 1];13:927–42. Available from:

·    Palmieri B, Laurino C, Vadala M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter [Internet]. 2019 Mar 1 [cited 2021 Mar 1];170(2):E93–9. Available from:

·    Blaskovich MAT, Kavanagh AM, Elliott AG, Zhang B, Ramu S, Amado M, et al. The antimicrobial potential of cannabidiol. Commun Biol [Internet]. 2021 Dec 1 [cited 2021 Mar 1];4(1). Available from:

·    Szachowicz-Petelska B, Łuczaj W, Wroński A, Jastrząb A, Dobrzyńska I. The Differential Effect of Cannabidiol on the Composition and Physicochemical Properties of Keratinocyte and Fibroblast Membranes from Psoriatic Patients and Healthy People. Membranes (Basel) [Internet]. 2021 Feb 4 [cited 2021 Mar 1];11(2):111. Available from:

·    Jarocka-Karpowicz I, Biernacki M, Wroński A, Gęgotek A, Skrzydlewska E. Cannabidiol effects on phospholipid metabolism in keratinocytes from patients with Psoriasis Vulgaris. Biomolecules [Internet]. 2020 Mar 1 [cited 2021 Mar 1];10(3). Available from:

·    Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014 Sep 2;124(9):3713–24.


· Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front Immunol [Internet]. 2018 Aug 3 [cited 2021 May 12];9(AUG). Available from:

·     Leussink VI, Husseini L, Warnke C, Hartung HP, Broussalis E, Kieseier BC. Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity [Internet]. Vol. 5, Therapeutic Advances in Neurological Disorders. Ther Adv Neurol Disord; 2012 [cited 2021 May 12]. p. 255–66. Available from:

·     Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: A systematic review. BMC Neurol [Internet]. 2009 Dec 4 [cited 2021 May 12];9. Available from:

    ·   Furgiuele A, Cosentino M, Ferrari M, Marino F. Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review [Internet]. Vol. 16, Journal of Neuroimmune Pharmacology. Springer; 2021 [cited 2021 May 12]. Available from:

    ·   Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis [Internet]. Vol. 9, Therapeutic Advances in Neurological Disorders. Ther Adv Neurol Disord; 2016 [cited 2021 May 12]. p. 9–30. Available from:

   ·     Centonze D. Advances in the management of multiple sclerosis spasticity: Multiple sclerosis spasticity nervous pathways. Eur Neurol [Internet]. 2014 Nov 7 [cited 2021 May 12];72:6–8. Available from:

    ·    Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis – PubMed [Internet]. [cited 2021 May 12]. Available from:

   ·    [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids] – PubMed [Internet]. [cited 2021 May 12]. Available from:

    ·    Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, et al. Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol [Internet]. 2011 Aug [cited 2021 May 12];163(7):1507–19. Available from:

  ·     Rudroff T, Sosnoff J. Cannabidiol to improve mobility in people with multiple sclerosis [Internet]. Vol. 9, Frontiers in Neurology. Frontiers Media S.A.; 2018 [cited 2021 May 12]. Available from:

  ·     Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis [Internet]. 2013 Nov [cited 2021 May 12];59:141–50. Available from:

Esto son sólo algunos ejemplos que muestran la evidencia científica que existe a día de hoy. A pesar de que la persecución del cannabis lastró la investigación durante décadas, lo cierto es que el ritmo en estos últimos años está siendo trepidante. En HEY CBD defendemos la apertura en investigación para que podamos aprovechar todo el potencial que el CBD nos ofrece.